glycovir
Trade name: Celgosivir
Small moleculeexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 2, 1999 (NCT00000791)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Reverse transcriptaseINHIBITOR
Reverse transcriptase inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCN1C[C@H](OC(=O)CCC)[C@@H](OC(=O)CCC)[C@H](OC(=O)CCC)[C@H]1COC(=O)CCC- Mol. weight
- 499.65 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297283 ↗
Also known as
- glycovir
- glycovir
- glycovir
- glycovir
- sc 49483
- sc-49483
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00000791 | Phase 2 | Nov 2, 1999 | G D Searle, Glaxo Wellcome, National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| G D Searle | For profit | 1 | 0 | 1 | 1999 |
| Glaxo Wellcome | For profit | 1 | 0 | 1 | 1999 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 1 | 1 | 1999 |
3 organizations
Page 1 / 1